[EN] NOVEL GLYCINE TRANSPORT INHIBITORS FOR THE TREATMENT OF PAIN<br/>[FR] NOUVEAUX INHIBITEURS DE TRANSPORT DE GLYCINE POUR LE TRAITEMENT DE LA DOULEUR
申请人:UNIV SYDNEY
公开号:WO2018132876A1
公开(公告)日:2018-07-26
The present invention relates to novel glycine transport inhibitor compounds and their use for treating pain.
本发明涉及新型甘氨酸转运抑制剂化合物及其用于治疗疼痛的用途。
Organic Compounds
申请人:Givaudan SA
公开号:US20200299229A1
公开(公告)日:2020-09-24
A flavour composition comprising a compound according to the formula (I) or edible salts thereof,
wherein
R
1
is an alkyl residue containing 6 to 20 carbon atoms, or an alkene residue containing from 9 to 25 carbon atoms with 1 to 6 double bonds, R
1
together with the carbonyl group to which it is attached is a residue of a carboxylic acid, and NR
2
R
3
, in which R
3
is H or together with R
2
and the N-atom to which they are attached, a 5-membered ring, is a residue of an amino acid, in particular a proteinogenic amino acid, ornithine, gamma-aminobutyric acid or beta alanine, or a 1-amino cycloalkyl carboxylic acid.
US5190782A
申请人:——
公开号:US5190782A
公开(公告)日:1993-03-02
Development of an <i>N</i>-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain
作者:Shannon N. Mostyn、Tristan Rawling、Sarasa Mohammadi、Susan Shimmon、Zachary J. Frangos、Subhodeep Sarker、Arsalan Yousuf、Irina Vetter、Renae M. Ryan、Macdonald J. Christie、Robert J. Vandenberg
DOI:10.1021/acs.jmedchem.8b01775
日期:2019.3.14
Inhibitors that target the glycinetransporter2, GlyT2, show promise as analgesics, but may be limited by their toxicity through complete or irreversible binding. Acyl-glycine inhibitors, however, are selective for GlyT2 and have been shown to provide analgesia in animal models of pain with minimal side effects, but are comparatively weak GlyT2 inhibitors. Here, we modify the simple acyl-glycine by
靶向甘氨酸转运蛋白 2、GlyT2 的抑制剂显示出作为镇痛剂的前景,但可能会通过完全或不可逆的结合而受到毒性的限制。然而,酰基甘氨酸抑制剂对 GlyT2 具有选择性,并且已被证明可在动物疼痛模型中提供镇痛作用,且副作用最小,但 GlyT2 抑制剂的作用相对较弱。在这里,我们通过合成具有一系列 l 和 d 构型的氨基酸头基的脂质类似物来修饰简单的酰基甘氨酸,以产生纳摩尔亲和力的选择性 GlyT2 抑制剂。强效抑制剂油酰-d-赖氨酸 (33) 对人和大鼠血浆和肝微粒体的降解也具有抗性,并且在大鼠腹腔注射后迅速吸收并容易穿过血脑屏障。